Trial reportDiabetes, obesity & metabolism2026
Additive Glucagonotropic and Insulinotropic Effects of Glucose-Dependent Insulinotropic Polypeptide and Alanine in Fasted Healthy Men.
Trial report in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06881472 (The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes
Who cites it
1 citing paper in PubMed.
- Additive Glucagonotropic and Insulinotropic Effects of Glucose-Dependent Insulinotropic Polypeptide and Alanine in Fasted Healthy Men.Diabetes, obesity & metabolism · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisGlucose-dependent insulinotropic polypeptide (GIP) is a bidirectional glucose-stabilising hormone potentiating insulin secretion at high glucose levels and glucagon secretion during normal-to-low plasma glucose levels. Preclinically, GIP and the amino acid alanine show synergistic glucagonotropic effects at low glucose levels. We therefore evaluated the separate and combined effects of GIP and alanine infusions on plasma glucose, glucagon and C-peptide in fasted, healthy men.
methodsIn this placebo-controlled, randomised, double-blind crossover study, 10 healthy men (mean age 22.9 ± 2.82 years, BMI 23.7 ± 2.07 kg/m
resultsAs expected, the infusions increased circulating levels of alanine and GIP according to the intervention. Alanine increased glucagon secretion, while GIP induced a more moderate glucagonotropic effect. The combination of alanine and GIP resulted in an additive increase in glucagon secretion with bsAUC CONCLUSIONS/
interpretationIn fasting healthy men, both GIP and alanine stimulate pancreatic hormone secretion, and combined administration additively enhances glucagon and C-peptide responses. Alanine availability modulates the metabolic actions of GIP and may influence its glucose-regulatory effects under fasting conditions.
trial registrationClinicalTrials.gov identifier: NCT06881472.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.